Related Experiment Video

Updated: Feb 10, 2026

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

11.7K

Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer

Tae-Ok Kim1, In-Jae Oh1,2, Bo Gun Kho1

  • 1Department of Internal Medicine, Chonnam National University Medical School, Gwangju, South Korea.

Thoracic Cancer
|May 16, 2018
PubMed
Abstract

Insights

Re-biopsy is feasible in advanced non-small cell lung cancer (NSCLC) patients after EGFR-TKI failure. This procedure is particularly successful in younger patients and those who previously responded to EGFR-TKIs, aiding treatment decisions.

Area of Science:

  • Oncology
  • Medical Diagnostics

Background:

  • EGFR-tyrosine kinase inhibitor (TKI) resistance necessitates understanding mechanisms for treatment guidance.
  • Re-biopsy is a potential method to identify resistance but faces practical challenges.

Purpose of the Study:

  • To assess the feasibility of re-biopsy in advanced non-small cell lung cancer (NSCLC) patients post-EGFR-TKI failure in real-world clinical settings.

Main Methods:

  • Retrospective review of advanced NSCLC patients treated with EGFR-TKIs between 2014-2016.
  • Analysis of re-biopsy success rates, complications, and EGFR mutation status (T790M) from various specimen types.
  • Multivariate analysis to identify factors associated with successful re-biopsy.

Main Results:

  • Re-biopsy was performed in 45.7% of eligible patients, with a success rate of 89.5%.
  • Complication rate was 8.6%, with pneumothorax being the most common.
  • T790M mutations were identified in 33.3% of patients with prior sensitizing mutations.

Conclusions:

  • Re-biopsy is a feasible strategy in advanced NSCLC patients experiencing EGFR-TKI failure.
  • Younger patients and those with a prior positive response to EGFR-TKIs were more likely to undergo successful re-biopsy.
Keywords:
EGFR mutationT790Mre-biopsy

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.0K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.0K
Mutations01:39

Mutations

Overview
94.6K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.6K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
40.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
774
Mutation, Gene Flow, and Genetic Drift01:09

Mutation, Gene Flow, and Genetic Drift

In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
64.6K